BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol. 2014;10:102-114. [PMID: 24322649 DOI: 10.1038/nrendo.2013.246] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, Zannino D, Hicks RJ. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2015;42:176-85. [PMID: 25209134 DOI: 10.1007/s00259-014-2906-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
2 Ayiomamitis GD, Notas G, Zaravinos A, Drygiannakis I, Georgiadou M, Sfakianaki O, Mastrodimou N, Thermos K, Kouroumalis E. Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity. Oncoscience 2014;1:457-67. [PMID: 25594044 DOI: 10.18632/oncoscience.58] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
3 Schillaci O, Spanu A, Palumbo B, Danieli R. SPECT/CT in neuroendocrine tumours. Clin Transl Imaging 2014;2:477-89. [DOI: 10.1007/s40336-014-0091-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D, Imperiale A. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. J Nucl Med 2016;57:1949-56. [PMID: 27811124 DOI: 10.2967/jnumed.116.179234] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 12.5] [Reference Citation Analysis]
5 Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Paraneoplastic endocrine syndromes. Endocrine-Related Cancer 2017;24:R173-90. [DOI: 10.1530/erc-17-0036] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
6 Amair-Pinedo F, Matos I, Saurí T, Hernando J, Capdevila J. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol 2017;12:757-74. [PMID: 29143176 DOI: 10.1007/s11523-017-0532-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Santhanam P, Taïeb D. Role of 18 F-FDOPA PET/CT imaging in endocrinology. Clin Endocrinol 2014;81:789-98. [DOI: 10.1111/cen.12566] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
8 Kanduluru AK, Srinivasarao M, Wayua C, Low PS. Evaluation of a Neurokinin-1 Receptor-Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging. Mol Imaging Biol 2020;22:377-83. [PMID: 31292915 DOI: 10.1007/s11307-019-01391-w] [Reference Citation Analysis]
9 Signore A, Lauri C, Auletta S, Varani M, Onofrio L, Glaudemans AWJM, Panzuto F, Marchetti P. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. Cancers (Basel) 2020;12:E781. [PMID: 32218303 DOI: 10.3390/cancers12040781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, Mortensen J, Federspiel B, Langer SW, Kjaer A. 18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. J Nucl Med 2021;62:808-15. [PMID: 33067340 DOI: 10.2967/jnumed.120.244798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
11 Sun J. Pancreatic neuroendocrine tumors. Intractable Rare Dis Res 2017;6:21-8. [PMID: 28357177 DOI: 10.5582/irdr.2017.01007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
12 Zappa M, Hentic O, Vullierme MP, Lagadec M, Ronot M, Ruszniewski P, Vilgrain V. Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible? Endocr Connect 2017;6:33-8. [PMID: 28069898 DOI: 10.1530/EC-16-0092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
13 Andersen TL, Baun C, Olsen BB, Dam JH, Thisgaard H. Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE. J Nucl Med 2020;61:228-33. [PMID: 31519803 DOI: 10.2967/jnumed.119.233015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
14 Lindström E, Lindsjö L, Sundin A, Sörensen J, Lubberink M. Evaluation of block-sequential regularized expectation maximization reconstruction of 68Ga-DOTATOC, 18F-fluoride, and 11C-acetate whole-body examinations acquired on a digital time-of-flight PET/CT scanner. EJNMMI Phys 2020;7:40. [PMID: 32542512 DOI: 10.1186/s40658-020-00310-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther 2017;10:551-7. [PMID: 28203088 DOI: 10.2147/OTT.S97584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
16 Steyn FJ, Tolle V, Chen C, Epelbaum J. Neuroendocrine Regulation of Growth Hormone Secretion. Compr Physiol 2016;6:687-735. [PMID: 27065166 DOI: 10.1002/cphy.c150002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
17 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Reference Citation Analysis]
18 Pettersson O, Fröss-Baron K, Crona J, Sundin A. Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients. Front Oncol 2020;10:193. [PMID: 32154181 DOI: 10.3389/fonc.2020.00193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39:1071-1084. [PMID: 24628514 DOI: 10.1111/apt.12698] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
20 Takenaka M, Amino T, Miyachi Y, Ogino C, Kondo A. Screening and evaluation of aptamers against somatostatin, and sandwich-like monitoring of somatostatin based on atomic force microscopy. Sensors and Actuators B: Chemical 2017;252:813-21. [DOI: 10.1016/j.snb.2017.06.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 Jordan B, Kellner J, Jordan K, Bähre M, Behrmann C, Zierz S. Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging. J Neurol 2016;263:641-8. [PMID: 26810725 DOI: 10.1007/s00415-016-8023-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Pape UF, Maasberg S, Jann H, Pschowski R, Krüger S, Prasad V, Denecke T, Wiedenmann B, Pascher A. Management of follow-up of neuroendocrine neoplasias. Best Pract Res Clin Endocrinol Metab 2016;30:129-40. [PMID: 26971849 DOI: 10.1016/j.beem.2016.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Czernin J, Sonni I, Razmaria A, Calais J. The Future of Nuclear Medicine as an Independent Specialty. J Nucl Med 2019;60:3S-12S. [PMID: 31481589 DOI: 10.2967/jnumed.118.220558] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
24 Raheem SJ, Schmidt BW, Solomon VR, Salih AK, Price EW. Ultrasonic-Assisted Solid-Phase Peptide Synthesis of DOTA-TATE and DOTA-linker-TATE Derivatives as a Simple and Low-Cost Method for the Facile Synthesis of Chelator-Peptide Conjugates. Bioconjug Chem 2021;32:1204-13. [PMID: 32645261 DOI: 10.1021/acs.bioconjchem.0c00325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Pettersson OJ, Fröss-Baron K, Crona J, Sundin A. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. Endocr Connect 2021;10:422-31. [PMID: 33875614 DOI: 10.1530/EC-21-0027] [Reference Citation Analysis]
26 Mankoff DA, Edmonds CE, Farwell MD, Pryma DA. Development of Companion Diagnostics. Semin Nucl Med 2016;46:47-56. [PMID: 26687857 DOI: 10.1053/j.semnuclmed.2015.09.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
27 Yohanathan L, Dossa F, St Germain AT, Golbafian F, Moulton CA, McGilvray ID, Greig PD, Serra S, Wei AC, Jhaveri KS, Gallinger S, Cleary SP. Management and surveillance of non-functional pancreatic neuroendocrine tumours: Retrospective review. Pancreatology 2019;19:360-6. [PMID: 30803874 DOI: 10.1016/j.pan.2019.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
28 Bailly C, Bodet-Milin C, Rousseau C, Faivre-Chauvet A, Kraeber-Bodéré F, Barbet J. Pretargeting for imaging and therapy in oncological nuclear medicine. EJNMMI Radiopharm Chem 2017;2:6. [PMID: 29503847 DOI: 10.1186/s41181-017-0026-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
29 Norlén O, Montan H, Hellman P, Stålberg P, Sundin A. Preoperative 68Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions. World J Surg 2018;42:498-505. [PMID: 29159606 DOI: 10.1007/s00268-017-4364-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
30 Hernandez Vargas S, Lin C, Voss J, Ghosh SC, Halperin DM, AghaAmiri S, Cao HST, Ikoma N, Uselmann AJ, Azhdarinia A. Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors. J Biomed Opt 2020;25. [PMID: 33300316 DOI: 10.1117/1.JBO.25.12.126002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Laskaratos F, Caplin M. Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours. European Journal of Surgical Oncology 2019;45:52-9. [DOI: 10.1016/j.ejso.2018.03.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
32 Lee MS, O'Neil BH. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol 2016;7:804-18. [PMID: 27747094 DOI: 10.21037/jgo.2016.08.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
33 Rosenkranz AA, Slastnikova TA, Karmakova TA, Vorontsova MS, Morozova NB, Petriev VM, Abrosimov AS, Khramtsov YV, Lupanova TN, Ulasov AV, Yakubovskaya RI, Georgiev GP, Sobolev AS. Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression. Front Pharmacol 2018;9:1331. [PMID: 30510514 DOI: 10.3389/fphar.2018.01331] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
34 Ito T, Jensen RT. Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol 2016;3:53-66. [PMID: 26834963 DOI: 10.2217/ije.15.29] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
35 Rozenblum L, Mokrane FZ, Yeh R, Sinigaglia M, Besson F, Seban RD, Chougnet CN, Revel-Mouroz P, Zhao B, Otal P, Schwartz LH, Dercle L. The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI. Abdom Radiol (NY) 2019;44:2474-93. [PMID: 30980115 DOI: 10.1007/s00261-019-01994-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
36 Liu F, Guo X, Liu T, Xu X, Li N, Xiong C, Li C, Zhu H, Yang Z. Evaluation of Pan-SSTRs Targeted Radioligand [64Cu]NOTA-PA1 Using Micro-PET Imaging in Xenografted Mice. ACS Med Chem Lett 2020;11:445-50. [PMID: 32292548 DOI: 10.1021/acsmedchemlett.9b00544] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Máté G, Šimeček J, Pniok M, Kertész I, Notni J, Wester HJ, Galuska L, Hermann P. The influence of the combination of carboxylate and phosphinate pendant arms in 1,4,7-triazacyclononane-based chelators on their 68Ga labelling properties. Molecules 2015;20:13112-26. [PMID: 26197305 DOI: 10.3390/molecules200713112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
38 de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol 2014;170:R173-83. [PMID: 24723670 DOI: 10.1530/EJE-14-0077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
39 Magnander T, Wikberg E, Svensson J, Gjertsson P, Wängberg B, Båth M, Bernhardt P. A novel statistical analysis method to improve the detection of hepatic foci of (111)In-octreotide in SPECT/CT imaging. EJNMMI Phys 2016;3:1. [PMID: 26782039 DOI: 10.1186/s40658-016-0137-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
40 Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 2018;18:837-60. [PMID: 29973077 DOI: 10.1080/14737140.2018.1496822] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
41 Zhu L, Xue HD, Sun H, Wang X, He YL, Jin ZY, Zhao YP. Isoattenuating insulinomas at biphasic contrast-enhanced CT: frequency, clinicopathologic features and perfusion characteristics. Eur Radiol. 2016;26:3697-3705. [PMID: 26815370 DOI: 10.1007/s00330-016-4216-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
42 Karlsson F, Antonodimitrakis PC, Eriksson O. Systematic screening of imaging biomarkers for the Islets of Langerhans, among clinically available positron emission tomography tracers. Nucl Med Biol. 2015;42:762-769. [PMID: 26138288 DOI: 10.1016/j.nucmedbio.2015.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP, Bollmann C, Kann PH, Bartsch DK. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1. World J Surg 2017;41:1521-7. [PMID: 28138732 DOI: 10.1007/s00268-017-3907-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
44 Kamikihara Y, Tanoue S, Kawahira M, Iwaya H, Arima S, Sasaki F, Nasu Y, Hashimoto S, Kanmura S, Higashi M, Gejima K, Ido A. A case of gallbladder neuroendocrine carcinoma diagnosed preoperatively using somatostatin receptor scintigraphy. Oncol Lett 2020;19:247-54. [PMID: 31897136 DOI: 10.3892/ol.2019.11101] [Reference Citation Analysis]
45 Malla S, Kumar P, Madhusudhan KS. Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review. Abdom Radiol (NY) 2021;46:919-35. [PMID: 32960304 DOI: 10.1007/s00261-020-02773-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Moody TW, Nuche-Berenguer B, Jensen RT. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol Diabetes Obes 2016;23:38-47. [PMID: 26702849 DOI: 10.1097/MED.0000000000000218] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
47 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
48 Bernsen MR, Kooiman K, Segbers M, van Leeuwen FW, de Jong M. Biomarkers in preclinical cancer imaging. Eur J Nucl Med Mol Imaging 2015;42:579-96. [PMID: 25673052 DOI: 10.1007/s00259-014-2980-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
49 Pavel ME, Sers C. WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. Endocrine-Related Cancer 2016;23:T135-54. [DOI: 10.1530/erc-16-0370] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
50 Honarvar H, Calce E, Doti N, Langella E, Orlova A, Buijs J, D'Amato V, Bianco R, Saviano M, Tolmachev V, De Luca S. Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. Sci Rep 2018;8:2998. [PMID: 29445216 DOI: 10.1038/s41598-018-21283-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
51 Rapicetta C, Falco F, Roncali M, Treglia G, Carbonelli C, Paci M, Marchi S, Lococo F. Solitary Choroidal Metastasis From Atypical Carcinoid of the Lung Detected by 68Ga DOTATATE PET/CT. Clinical Nuclear Medicine 2015;40:e319-20. [DOI: 10.1097/rlu.0000000000000660] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
52 Ryu JH, Lee S, Son S, Kim SH, Leary JF, Choi K, Kwon IC. Theranostic nanoparticles for future personalized medicine. Journal of Controlled Release 2014;190:477-84. [DOI: 10.1016/j.jconrel.2014.04.027] [Cited by in Crossref: 124] [Cited by in F6Publishing: 107] [Article Influence: 15.5] [Reference Citation Analysis]
53 Alessandrino F, Ivanovic AM, Yee EU, Radulovic D, Souza D, Mortele KJ. MDCT and MRI of the ampulla of Vater. Part I: technique optimization, normal anatomy, and epithelial neoplasms. Abdom Imaging 2015;40:3274-91. [PMID: 26306515 DOI: 10.1007/s00261-015-0528-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
54 Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol 2016; 22(45): 9944-9953 [PMID: 28018101 DOI: 10.3748/wjg.v22.i45.9944] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
55 Franco Machado J, Silva RD, Melo R, G Correia JD. Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics. Molecules 2018;24:E49. [PMID: 30583594 DOI: 10.3390/molecules24010049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
56 Granata V, Fusco R, Setola SV, Castelguidone ELD, Camera L, Tafuto S, Avallone A, Belli A, Incollingo P, Palaia R, Izzo F, Petrillo A. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge. Radiol Oncol. 2019;53:373-387. [PMID: 31652122 DOI: 10.2478/raon-2019-0040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
57 Schüler E, Österlund A, Forssell-Aronsson E. The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice. Acta Oncol 2016;55:68-76. [PMID: 25813472 DOI: 10.3109/0284186X.2015.1027001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
58 Patil VA, Goroshi MR, Shah H, Malhotra G, Hira P, Sarathi V, Lele VR, Jadhav S, Lila A, Bandgar TR, Shah NS. Comparison of 68Ga-DOTA-NaI3-Octreotide/tyr3-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome. World J Nucl Med 2020;19:99-105. [PMID: 32939195 DOI: 10.4103/wjnm.WJNM_24_19] [Reference Citation Analysis]
59 Amouroux G, Zhang Z, Pan J, Jenni S, Zhang C, Hundal-Jabal N, Colpo N, Zeisler J, Lin KS, Bénard F. Synthesis and evaluation of a 68Ga-labeled bradykinin B1 receptor agonist for imaging with positron emission tomography. Bioorg Med Chem 2017;25:690-6. [PMID: 27908753 DOI: 10.1016/j.bmc.2016.11.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
60 Satapathy S, Mittal BR, Sood A, Sood A, Kapoor R, Gupta R. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors. Clin Nucl Med 2020;45:e393-9. [PMID: 32604121 DOI: 10.1097/RLU.0000000000003170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP. Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues. Seminars in Nuclear Medicine 2016;46:215-24. [DOI: 10.1053/j.semnuclmed.2016.01.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
62 Salahshour F, Taslimi R, Moosavi NS, Yazdi NA, Esfandbod M. Pancreatic Neuroendocrine Tumor presenting as a diffuse pancreatic enlargement, case report and review of literature. J Radiol Case Rep 2021;15:11-20. [PMID: 33717403 DOI: 10.3941/jrcr.v15i1.3822] [Reference Citation Analysis]
63 Ilan E, Sandström M, Velikyan I, Sundin A, Eriksson B, Lubberink M. Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast. J Nucl Med 2017;58:744-9. [PMID: 27789716 DOI: 10.2967/jnumed.116.180380] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
64 Fernández-bañares F, Accarino A, Balboa A, Domènech E, Esteve M, Garcia-planella E, Guardiola J, Molero X, Rodríguez-luna A, Ruiz-cerulla A, Santos J, Vaquero E. Diarrea crónica: definición, clasificación y diagnóstico. Gastroenterología y Hepatología 2016;39:535-59. [DOI: 10.1016/j.gastrohep.2015.09.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
65 Merola E, Pavel ME, Panzuto F, Capurso G, Cicchese N, Rinke A, Gress TM, Iannicelli E, Prosperi D, Pizzichini P, Prasad V, Kump P, Lipp R, Partelli S, Falconi M, Wiedenmann B, Delle Fave G. Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. The Journal of Clinical Endocrinology & Metabolism 2017;102:1486-94. [DOI: 10.1210/jc.2016-3732] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
66 Segelov E, Chan D, Lawrence B, Pavlakis N, Kennecke HF, Jackson C, Law C, Singh S. Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. J Glob Oncol 2017;3:380-8. [PMID: 28831446 DOI: 10.1200/JGO.2016.006916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 July M, Santhanam P, Giovanella L, Treglia G. Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes. Clin Physiol Funct Imaging 2018;38:4-9. [DOI: 10.1111/cpf.12391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
68 Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R; Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017;105:266-280. [PMID: 28351033 DOI: 10.1159/000471880] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 14.4] [Reference Citation Analysis]
69 Därr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M, Balint B, Jochmanova I, Prchal JT, Lechan RM, Tischler AS, Popovic V, Miljic D, Adams KT, Prall FR, Ling A, Golomb MR, Ferguson M, Nilubol N, Chen CC, Chew E, Taïeb D, Stratakis CA, Fojo T, Yang C, Kebebew E, Zhuang Z, Pacak K. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer 2016;23:899-908. [PMID: 27679736 DOI: 10.1530/ERC-16-0231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
70 Kong G, Callahan J, Hofman MS, Pattison DA, Akhurst T, Michael M, Eu P, Hicks RJ. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2017;44:476-89. [DOI: 10.1007/s00259-016-3527-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
71 Ducry J, Gomez F, Prior JO, Boubaker A, Matter M, Monti M, Pu Y, Pitteloud N, Portmann L. Mid-gut ACTH-secreting neuroendocrine tumor unmasked with (18)F-dihydroxyphenylalanine-positron emission tomography. Endocrinol Diabetes Metab Case Rep 2015;2015:140104. [PMID: 25861450 DOI: 10.1530/EDM-14-0104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Saha A, Tso S, Rabski J, Sadeghian A, Cusimano MD. Machine learning applications in imaging analysis for patients with pituitary tumors: a review of the current literature and future directions. Pituitary 2020;23:273-93. [PMID: 31907710 DOI: 10.1007/s11102-019-01026-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
73 Liu JB, Baker MS. Surgical Management of Pancreatic Neuroendocrine Tumors. Surg Clin North Am. 2016;96:1447-1468. [PMID: 27865287 DOI: 10.1016/j.suc.2016.07.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
74 Basuroy R, Sarker D, Quaglia A, Srirajaskanthan R, Ramage J. Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream? International Journal of Endocrine Oncology 2015;2:201-15. [DOI: 10.2217/ije.15.9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
75 Duan K, Ezzat S, Asa SL, Mete O. Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP. In: La Rosa S, Sessa F, editors. Pancreatic Neuroendocrine Neoplasms. Cham: Springer International Publishing; 2015. pp. 125-39. [DOI: 10.1007/978-3-319-17235-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Zhu H, Ying L, Tang W, Yang X, Sun B. Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms? Radiol med 2017;122:319-26. [DOI: 10.1007/s11547-017-0727-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
77 Cavallaro A, Zanghì A, Cavallaro M, Lo Menzo E, Di Carlo I, Di Vita M, Cardì F, Piccolo G, Di Mattia P, Cappellani A. The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report.Int J Surg. 2014;12 Suppl 1:S225-S231. [PMID: 24862665 DOI: 10.1016/j.ijsu.2014.05.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
78 Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol 2016;65:1017-30. [PMID: 27395013 DOI: 10.1016/j.jhep.2016.06.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
79 De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Ann Nucl Med 2016;30:234-41. [PMID: 26753628 DOI: 10.1007/s12149-015-1056-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
80 Manoharan J, Albers MB, Bartsch DK. The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer 2017;24:T209-25. [PMID: 28790162 DOI: 10.1530/ERC-17-0231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
81 Degnan AJ, Tadros SS, Tocchio S. Pediatric Neuroendocrine Carcinoid Tumors: Review of Diagnostic Imaging Findings and Recent Advances. AJR Am J Roentgenol 2017;208:868-77. [PMID: 28199138 DOI: 10.2214/AJR.16.17287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]